CASP3 and acquired polycythemia vera: Although these inhibitors do represent a promising adjunctive treatment option or a second line intervention for PV patients, their testing in PV clinical trials are not justified unless experimental proof of concept and the mechanisms of action of caspase-3 in PV are resolved.